A comparison of oral and parenteral routes for therapeutic vaccination with HSV-2 ISCOMs in mice; cytokine profiles, antibody responses and protection

Antiviral Research

Volumn 49, Issue 2, 2001, Pages 83-99

  Mohamedi, S A ^a   Heath, A W ^a   Jennings, R ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Antibody responses; Cytokine responses; HSV 2; Therapeutic immunisation

Indexed keywords

ANTIBODY; CYTOKINE; GAMMA INTERFERON; HERPES VACCINE; INTERLEUKIN 2; INTERLEUKIN 4; ISCOM; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ACTIVE IMMUNIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ARTICLE; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DRUG FORMULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; FEMALE; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HOST; HUMORAL IMMUNITY; IMMUNE STATUS; MOUSE; MUCOSA; NONHUMAN; PRIORITY JOURNAL; RECURRENT INFECTION; SPLEEN CELL; SUPERNATANT; VACCINATION; VIRUS REACTIVATION;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CYTOKINES; FEMALE; HERPES GENITALIS; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; HERPESVIRUS VACCINES; ISCOMS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; VACCINATION;

HUMAN HERPESVIRUS 1; HUMAN HERPESVIRUS 2;

EID: 0035251001     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(00)00142-X     Document Type: Article

References (73)

1. Cervical antibody responses to a herpes simplex virus type 2 glycoprotein subunit vaccine
2. The IgA and subclass IgG responses and protection in mice immunized with influenza antigens administered as ISCOMs, with FCA, ALH or as infectious virus
3. Herpes simplex virus-specific cytolytic T lymphocytes restricted to a normally low responder H-2 allele are protective in vivo
4. A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease
5. T cell recognition and cytokine production elicited by common and type-specific glycoproteins of herpes simplex virus type 1 and 2
6. Hepatitis B virus immunopathogenesis
7. The role of helper T cell products in mouse B cell differentiation and isotype regulation
8. IgG2a restriction of murine antibodies elicited by viral infections
9. Gamma-interferon production appears to predict time of recurrences of herpes labialis
10. Antibody responses and protection in mice immunized with herpes simplex virus type 1 immunostimulating complex preparations
11. Biochemical characterisation of herpes simplex type 1 immunostimulating complexes (ISCOMs): A multi-glycoprotein structure
12. Acute and latent infections of mice immunized with HSV-1 ISCOM vaccine
13. Antiviral activities of human monoclonal antibodies to herpes simplex virus
14. Specific secretory immune responses in the female genital tract following intranasal immunization with a recombinant adenovirus expressing glycoprotein B or herpes simplex virus
15. Long-term immunity and protection against herpes simplex virus type 2 in the murine female genital tract after mucosal but not systemic immunization
16. Immunogenicity of influenza and HSV-2 mixed antigen ISCOMs in mice
17. Expression of seven herpes simplex virus type 1 glycoproteins (gB, gC, gD, gG, gH and gI): Comparative protection against lethal challenge in mice
18. The importance of MHC-I and MHC-II responses in vaccine efficacy against lethal herpes simplex virus type 1 challenge
19. Adjuvants - A balance between toxicity and adjuvanticity
20. Immune responses in mice induced by HSV-1 glycoproteins presented with ISCOMs or NISV delivery systems
21. Antigen presenting lipsomes are effective in treatment of recurrent herpes simplex virus genitalis in guinea-pigs
22. The IgG subclass responses to influenza virus haemagglutinin in the mouse: Effect of route of inoculation
23. The immunostimulating complex (ISCOM) is an efficient mucosal delivery system for respiratory syncytial virus (RSV) enveloped antigens inducing high local and systemic antibody responses
24. Vaccines and vaccine delivery systems: Experience with HSV, influenza and mucosal routes of immunisation
25. + and CD8-T lymphocytes and macrophage subsets in the control of a generalized virus infection
26. Immune responses and protective effect in mice vaccinated orally with surface sporozoite protein of Eimeria falciformis in ISCOMs
27. Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes
28. Induction of mucosal immunity against herpes simplex virus by plasmid DNA immunisation
29. + T lymphocytes
30. Neutralization capacity and antibody dependent cell-mediated cytotoxicity of separated IgG subclasses 1, 3 and 4 against herpes simplex virus
31. The mucosal immune system: From fundamental concepts to vaccine development
32. Induction of a protective immune response by mucosal vaccination with a DISC HSV-1 vaccine
33. Double-blind, placebo-controlled trial of herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection
34. Risk factors for sexual transmission of genital herpes
35. Herpes simplex virus type 1 glycoproteins gB, gC and gD are major targets for CD4 T-lymphocyte cytotoxicity in HLA-DR expressing human epidermal keratinocytes
36. Neutralising antibodies inhibit axonal spread of herpes simplex virus type 1 to epidermal cells in vitro
37. Alphaherpes viruses: Herpes simplex and varicella-zoster
38. Interleukin-4 causes delayed virus clearance in influenza virus-infected mice
39. ISCOM, a novel structure for antigen presentation of membrane proteins from enveloped viruses
40. ISCOM, a delivery system for parenteral and mucosal vaccination
41. ISCOM: A delivery system for neonates and for mucosal administration
42. Th1 and Th2 cells: Different patterns of lymphokine secretion lead to different functional properties
43. The expanding universe of T-cell subsets, Th1, Th2 and more
44. Immunostimulating complexes containing Quil A and protein antigen prime class I MHC-restricted T lymphocytes in vivo and are immunogenic by the oral route
45. Immune-stimulating complexes as adjuvants for inducing local and systemic immunity after oral immunisation with protein antigens
46. Membrane phenotype of murine effector and suppressor T cells involved in delayed type hypersensitivity and protective immunity to herpes simplex virus
47. The immune response to herpes simplex virus
48. Mechanism of virus-induced Ig subclass shifts
49. High frequency of CD8+ cytotoxic T-lymphocyte precursors specific for herpes simplex viruses in persons with genital herpes
50. Induction of mucosal immunity against herpes simplex virus type 1 in the mouse protects against ocular infection and establishment of latency
51. Cell-mediated immunity and immunosuppression in herpes simplex virus infection
52. Induction in vitro of primary cytotoxic T-lymphocyte responses with DNA encoding herpes simplex virus proteins
53. The effect of adjuvants on the efficacy of a recombinant herpes simplex virus glycoprotein vaccine
54. Protection of mice against an influenza virus infection by oral vaccination with viral nucleoprotein incorporated in immunostimulating complexes
55. +, CD8- T cells and is restricted to the DR region of the MHC complex
56. ISCOMs containing purified Quillaja Saponins upregulate both Th1-like and Th2-like immune responses
57. Correlation between a history of herpes labialis, experimental radiation (UVR)-induced herpes labialis, neutralising antibody (NEUTAB) and IL-2 and γ-IFN production by PBMC
58. The concept of immune-based therapies in chronic viral infections
59. Herpes immunisation-on the threshold
60. Oral tolerance
61. Induction of CD8+ cytotoxic T cells by immunisation with purified HIV-1 envelope proteins in ISCOMs
62. Human herpes simplex virus (HSV) specific CD8+ CTL clones recognize HSV-2 infected fibroblasts and treatment with IFN-γ or when virion host shutoff functions are disabled
63. Significance of local γ-interferon in recurrent herpes simplex virus infection
64. Intranasal immunisation of mice with herpes simplex virus type 2 recombinant gD2: The effect of adjuvants on mucosal and serum antibody responses
65. Involvement of IL-2 and IFN-γ in the immune response induced by influenza virus ISCOMs
66. Immunomodulation by Quillaja saponaria adjuvant formulations: In vivo stimulation of interleukin-12 and its effects on the antibody response
67. Modulation of cytokine responses by ISCOMs
68. Specific lung mucosal and systemic immune responses after oral immunisation of mice with Salmonella typhimurium aro A, Salmonella typhi Ty21a, and invasive Escherichia coli expressing recombinant pertussis toxin subunit
69. New strategies for using mucosal immunisation to achieve more effective immunisations
70. Passive immunization of the vagina protects mice against vaginal transmission of genital herpes infections
71. Ultraviolet-B irradiation alters cytokine production by immune lymphocytes in herpes simplex virus-infected mice
72. Immunomodulatory effects of HSV-2 glycoprotein D in HSV-1 infected mice; implication for immunotherapy of recurrent HSV infection